ID

28322

Description

A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin; ODM derived from: https://clinicaltrials.gov/show/NCT01077739

Link

https://clinicaltrials.gov/show/NCT01077739

Keywords

Versions (1)
  1. 1/4/18 1/4/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

January 4, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Cancer NCT01077739

English

Eligibility Colorectal Cancer NCT01077739

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients >/=18 years of age
Description

Adult | Age

Data type

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
metastatic colorectal cancer
Description

Colorectal cancer metastatic

Data type

boolean

Alias
UMLS CUI [1]
C0948380
at least 1 measurable lesion according to recist v. 1.1
Description

Measurable lesion Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
patients with disease progression with prior folfiri + avastin therapy who are not candidates for primary metastasectomy
Description

Disease Progression | FOLFIRI Regimen | Avastin | Absence Schedule Metastasectomy Primary

Data type

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2]
C1880658
UMLS CUI [3]
C1135130
UMLS CUI [4,1]
C0332197
UMLS CUI [4,2]
C0030703
UMLS CUI [4,3]
C2363923
UMLS CUI [4,4]
C0205225
disease progression </= 8 weeks after last dose of avastin
Description

Disease Progression

Data type

boolean

Alias
UMLS CUI [1]
C0242656
ecog </=2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
no more than 8 weeks between 1st-line treatment with folfiri + avastin and 2nd-line treatment with xelox or folfox + avastin
Description

First line treatment | FOLFIRI Regimen | Avastin | Second line treatment | XELOX | FOLFOX Regimen

Data type

boolean

Alias
UMLS CUI [1]
C1708063
UMLS CUI [2]
C1880658
UMLS CUI [3]
C1135130
UMLS CUI [4]
C1710038
UMLS CUI [5]
C1956962
UMLS CUI [6]
C0392943
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
disease progression > 8 weeks after last avastin administration
Description

Disease Progression | Status post Avastin

Data type

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C1135130
clinically significant cardiovascular disease
Description

Cardiovascular Disease

Data type

boolean

Alias
UMLS CUI [1]
C0007222
cns disease except for treated brain metastasis
Description

CNS disorder | Exception Metastatic malignant neoplasm to brain Treated

Data type

boolean

Alias
UMLS CUI [1]
C0007682
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0220650
UMLS CUI [2,3]
C1522326
history of other malignancies within 2 years prior to start of study treatment (with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix)
Description

Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin | Exception Curative treatment Carcinoma in situ of uterine cervix

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1273390
UMLS CUI [2,3]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0553723
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1273390
UMLS CUI [4,3]
C0851140
major surgery, open biopsy, or significant traumatic injury within 28 days prior to start of study treatment
Description

Major surgery | Incisional biopsy | Traumatic injury

Data type

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C0184922
UMLS CUI [3]
C3263723
Back to the top of the page

Similar models

Eligibility Colorectal Cancer NCT01077739

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients >/=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Colorectal cancer metastatic
Item
metastatic colorectal cancer
boolean
C0948380 (UMLS CUI [1])
Measurable lesion Quantity
Item
at least 1 measurable lesion according to recist v. 1.1
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Disease Progression | FOLFIRI Regimen | Avastin | Absence Schedule Metastasectomy Primary
Item
patients with disease progression with prior folfiri + avastin therapy who are not candidates for primary metastasectomy
boolean
C0242656 (UMLS CUI [1])
C1880658 (UMLS CUI [2])
C1135130 (UMLS CUI [3])
C0332197 (UMLS CUI [4,1])
C0030703 (UMLS CUI [4,2])
C2363923 (UMLS CUI [4,3])
C0205225 (UMLS CUI [4,4])
Disease Progression
Item
disease progression </= 8 weeks after last dose of avastin
boolean
C0242656 (UMLS CUI [1])
ECOG performance status
Item
ecog </=2
boolean
C1520224 (UMLS CUI [1])
First line treatment | FOLFIRI Regimen | Avastin | Second line treatment | XELOX | FOLFOX Regimen
Item
no more than 8 weeks between 1st-line treatment with folfiri + avastin and 2nd-line treatment with xelox or folfox + avastin
boolean
C1708063 (UMLS CUI [1])
C1880658 (UMLS CUI [2])
C1135130 (UMLS CUI [3])
C1710038 (UMLS CUI [4])
C1956962 (UMLS CUI [5])
C0392943 (UMLS CUI [6])
Item Group
C0680251 (UMLS CUI)
Disease Progression | Status post Avastin
Item
disease progression > 8 weeks after last avastin administration
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1135130 (UMLS CUI [2,2])
Cardiovascular Disease
Item
clinically significant cardiovascular disease
boolean
C0007222 (UMLS CUI [1])
CNS disorder | Exception Metastatic malignant neoplasm to brain Treated
Item
cns disease except for treated brain metastasis
boolean
C0007682 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0220650 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Squamous cell carcinoma of skin | Exception Curative treatment Carcinoma in situ of uterine cervix
Item
history of other malignancies within 2 years prior to start of study treatment (with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix)
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0553723 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C1273390 (UMLS CUI [4,2])
C0851140 (UMLS CUI [4,3])
Major surgery | Incisional biopsy | Traumatic injury
Item
major surgery, open biopsy, or significant traumatic injury within 28 days prior to start of study treatment
boolean
C0679637 (UMLS CUI [1])
C0184922 (UMLS CUI [2])
C3263723 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial